Extended Time in ED Linked to Reported Racial Discrimination and Patient Dissatisfaction
September 24th 2024Boarding times in the emergency department (ED) have risen nationally, but the implications for health equity have remained understudied. This study investigated whether prolonged ED boarding contributed to perceived racial discrimination and dissatisfaction with care.
Read More
A Silent Risk: The Critical Role of Awareness and Early Detection in Familial Hypercholesterolemia
September 24th 2024September 24 celebrates Familial Hypercholesterolemia Awareness Day, which recognizes the importance of screening measures, education, and advocacy in a lesser-known, underdiagnosed cardiovascular condition.
Read More
FDA Approves First Self-Administered Nasal Spray Flu Vaccine
September 23rd 2024The FDA has approved FluMist (AstraZeneca) for self-administration by adults up to age 49 years or for caregiver administration for children aged 2 to 17 years, making it the first self-administered flu vaccine option.
Read More
Advancing Research on Alopecia Areata Treatment and Epidemiology
September 23rd 2024Arash Mostaghimi, MD, MPA, MPH, assistant professor of dermatology, director of the inpatient dermatology consult service, and codirector of the Complex Medical Dermatology Fellowship at Brigham & Women's Hospital, draws attention to the challenges in identifying specific treatment targets in alopecia areata and the development of effective outcome measures for clinical trials.
Read More
FDA Approves Bimekizumab for Psoriatic Arthritis, Nonradiographic AxSpA, Ankylosing Spondylitis
September 23rd 2024Bimekizumab-bkzx (Bimzelx) is now FDA approved for 4 chronic immune-mediated inflammatory diseases: psoriatic arthritis, nonradiographic axial spondyloarthritis (axSpA), ankylosing spondylitis, and moderate to severe plaque psoriasis.
Read More
A Decade of Progress in Familial Hypercholesterolemia Awareness, Treatment
September 23rd 2024On day 1 of the Family Heart Global Summit, speakers highlighted the critical need for awareness, early diagnosis, and innovative treatment options for familial hypercholesterolemia, sharing significant strides made in the field over the past decade.
Read More
Medicare High-Value Drug List Model Could Lower Out-of-Pocket Costs for 4 in 10 Beneficiaries
September 23rd 2024The proposed Medicare High-Value Drug List Model, also known as the Medicare $2 Drug List, could have modestly reduced out-of-pocket costs for 38% of beneficiaries if implemented in 2021.
Read More
CMMI's Latest Payment Models Address Health Disparities, but Challenges Remain
September 22nd 2024"As CMMI continues to test new equity adjustments, it is important that changes be grounded in scientific principles with extensive testing and validation to ensure the tightest linkage to social needs and health outcomes for underserved communities across the entire US," authors wrote.
Read More
New Research Unearths Evidence of Global Metabolic Disruption in Patients With SMA
September 21st 2024A recent analysis investigated the state of metabolic disruption experienced by patients with spinal muscular atrophy (SMA), adding to the literature on nutritional and metabolic complications linked to SMA.
Read More
FDA Approves Isatuximab With VRd as First-Line Option for Transplant-Ineligible Multiple Myeloma
September 20th 2024Isatuximab (Sarclisa) with bortezomib, lenalidomide, and dexamethasone (VRd) is now an approved option for adults who cannot receive an autologous stem cell transplant to treat their newly diagnosed multiple myeloma.
Read More